Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,530
datasets available to search
ShareScore release 0.9.0
Dataset results
3,530 results for “Non-small cell lung cancer”
Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer
<p>Polygenic risk score weights derived using LDpred for hypothyroidism and thyroid medication use.</p>
Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
<p>Different biomarkers based on genomics variants have been used to predict the response of patients treated with PD-1/programmed death receptor 1 ligand (PD-L1) blockade. We aimed to use deep-learning algorithm to estimate clinical benefit in patients with non-small-cell lung cancer (NSCLC) before immunotherapy. Peripheral blood samples or tumor tissues of 915 patients from three independent centers were profiled by whole-exome sequencing or next-generation sequencing. Based on convolutional neural network (CNN) and three conventional machine learning (cML) methods, we used multi-panels to train the models for predicting the durable clinical benefit (DCB) and combined them to develop a nomogram model for predicting prognosis. In the three cohorts, the CNN achieved the highest area under the curve of predicting DCB among cML, PD-L1 expression, and tumor mutational burden (area under the curve [AUC] = 0.965, 95% confidence interval [CI]: 0.949–0.978, <em>P</em> < 0.001; AUC =0.965, 95% CI: 0.940–0.989, <em>P</em> < 0.001; AUC = 0.959, 95% CI: 0.942–0.976, <em>P</em> < 0.001, respectively). Patients with CNN-high had longer progression-free survival (PFS) and overall survival (OS) than patients with CNN-low in the three cohorts. Subgroup analysis confirmed the efficient predictive ability of CNN. Combining three cML methods (CNN, SVM, and RF) yielded a robust comprehensive nomogram for predicting PFS and OS in the three cohorts (each <em>P</em> < 0.001). The proposed deep-learning method based on mutational genes revealed the potential value of clinical benefit prediction in patients with NSCLC and provides novel insights for combined machine learning in PD-1/PD-L1 blockade.</p>
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
ClinicalTrials.gov study NCT06582940. IPD Sharing: NO. Countries: 1. Publications: 8.
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
ClinicalTrials.gov study NCT04980716. IPD Sharing: Not stated. Countries: 1. Publications: 25.
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00021060. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
ClinicalTrials.gov study NCT02504372. IPD Sharing: YES. Countries: 0. Publications: 1.
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00673777. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT00874107. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)
ClinicalTrials.gov study NCT03976518. IPD Sharing: Not stated. Countries: 1. Publications: 29.
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00064012. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03539536. IPD Sharing: YES. Countries: 26. Publications: 1.
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT00576914. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04835025. IPD Sharing: UNDECIDED. Countries: 1. Publications: 13.
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT01255150. IPD Sharing: Not stated. Countries: 5. Publications: 3.
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00372073. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00062062. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT05341583. IPD Sharing: NO. Countries: 1. Publications: 0.
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT02106546. IPD Sharing: YES. Countries: 38. Publications: 1.
Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
ClinicalTrials.gov study NCT00922584. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
ClinicalTrials.gov study NCT00654420. IPD Sharing: YES. Countries: 0. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.